Dr. Tilly Discusses Study of POLA-R-CHP in DLBCL

Video

Herve Tilly, MD, PhD, Centre Henri Becquerel, discusses a study of polatuzumab vedotin combined with rituximab (Rituxan), cyclophosphamide, doxorubicin and prednisone (PLOA-R-CHP) in patients with previously untreated diffuse large B-cell lymphoma.

Herve Tilly, MD, PhD, Centre Henri Becquerel, discusses a study of polatuzumab vedotin combined with rituximab (Rituxan), cyclophosphamide, doxorubicin and prednisone (PLOA-R-CHP) in patients with previously untreated diffuse large B-cell lymphoma (DLBCL).

Related Videos
Elias Jabbour, MD, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Debu Tripathy, MD
Sunil Iyer, MD
Zeynep Eroglu, MD
Zeynep Eroglu, MD
Yang Yang Hartwich, PhD
Manmeet Singh Ahluwalia, MD
John Paul Diaz, MD
Scott Kopetz, MD, PhD, FACP
Related Content
Xianping Lu, PhD

Chidamide Plus R-CHOP Approved in China for MYC/BCL2–Expressing DLBCL

April 30th 2024
Article
Matthew Lunning, DO, FACP

Lunning and Mehta-Shah Unpack Treatment Needs and Future Directions in PTCL

December 21st 2023
Podcast
Richard Maziarz, MD, medical director, Blood & Marrow Transplant & Cellular Therapy Program, Oregon Health and Science University

Prophylactic Itacitinib May Safely Mitigate CRS Following Axi-Cel Administration in Lymphoma

April 16th 2024
Article
Matthew Lunning, DO, FACP

Lunning and Nastoupil Highlight Treatment Considerations and Ongoing Research in Follicular Lymphoma

October 30th 2023
Podcast
Levi Garraway, MD, PhD, of Roche

Glofitamab Plus Chemotherapy Meets OS End Point in R/R DLBCL

April 15th 2024
Article
In case you missed it, these were the key regulatory decisions made by the FDA in March 2024.

March Approval Madness: OncLive’s Roundup of FDA Decisions in Oncology

April 13th 2024
Article